The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
| Autor: | Jennifer R. Kramer, Yongquan Dong, Christine Hartman, Donna L. White, Kathryn E. Royse, David S. Lakomy, Suchismita Raychaudhury, Peter Richardson, Alison Yoder, Lilie L. Lin, Elizabeth Y. Chiao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty HIV Infections 03 medical and health sciences 0302 clinical medicine Anal carcinoma Internal medicine Squamous cell carcinoma Genetics medicine Anal cancer Humans Protease inhibitor (pharmacology) Veterans Affairs RC254-282 Veterans Proportional hazards model business.industry Hazard ratio Anal Squamous Cell Carcinoma HIV Neoplasms. Tumors. Oncology. Including cancer and carcinogens Retrospective cohort study Chemoradiotherapy Middle Aged Protease inhibitors medicine.disease Anus Neoplasms 030104 developmental biology Treatment Outcome Chemoradiation 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female business Febrile neutropenia Research Article |
| Zdroj: | BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021) BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | BackgroundThe incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase toxicities in patients undergoing chemoradiation. This study examines treatment outcomes and toxicities in PLWH managed with and without protease inhibitors who are receiving chemoradiation for anal cancer.MethodsPatient demographic, HIV management, and cancer treatment information were extracted from multiple Veterans Affairs databases. Patients were also manually chart reviewed. Among PLWH undergoing chemoradiation for anal carcinoma, therapy outcomes and toxicities were compared between those treated with and without protease inhibitors at time of cancer treatment. Statistical analysis was performed using chi-square, Cox regression analysis, and logistic regression.ResultsA total of 219 PLWH taking anti-retroviral therapy undergoing chemoradiation for anal cancer were identified and included in the final analysis. The use of protease inhibitors was not associated with any survival outcome including colostomy-free survival, progression-free survival, or overall survival (all adjusted hazard ratiop-values> 0.05). Regarding toxicity, protease inhibitor use was not associated with an increased odds of hospitalizations or non-hematologic toxicities; however, protease inhibitor use was associated with increased hospitalizations for hematologic toxicities, including febrile neutropenia (p ConclusionThe use of protease inhibitors during chemoradiation for anal carcinoma was not associated with any clinical outcome or increase in non-hematologic toxicity. Their use was associated with increased hospitalizations for hematologic toxicities. Further prospective research is needed to evaluate the safety and efficacy of protease inhibitors for patients undergoing chemoradiation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|